期刊文献+

Lnc RNA在食管癌中的研究进展 被引量:2

Research progress of Lnc RNA in esophageal cancer
下载PDF
导出
摘要 食管癌(esophageal cancer,EC)已经成为世界第六大死亡原因和第八种最常见的癌症,是最致命的恶性肿瘤之一,亚洲地区的主要病理类型是食管鳞癌(esophageal squamous cell carcinoma,ESCC)。诊断EC的传统生物标志物包括CEA、CA19-9和SCCA等。由于传统生物标志物的诊断敏感性偏低和特异性不强,EC的早期诊断仍较困难,因此导致预后欠佳。EC存在一个复杂而重要的基因调控网络,但其发病机制尚不清楚。长链非编码RNA(long non-coding RNA,Lnc RNA)可预测多种恶性肿瘤的发生或预后,并可能成为一类新的肿瘤标记物及潜在的治疗靶标。本综述主要阐述Lnc RNA在EC中的作用和调控机制,并讨论其作为诊断、治疗和预后生物标志物的潜在临床应用。 Esophageal cancer ranks eighth among the most common malignant tumors in the world,which is the sixth leading cause of cancer-related death,and is one of the most lethal malignant tumors.Esophageal squamous cell carcinoma is the main pathological type of esophageal cancer in Asia.Traditional biomarkers for diagnosis of esophageal cancer include CEA,CA19-9 and SCCA.However,the early diagnosis of esophageal cancer is still difficult due to the lack of high sensitivity and specificity,resulting in poor prognosis.Recent studies have shown that Lnc RNA can predict the occurrence and prognosis of many malignant tumors,and may become a new class of tumor markers and potential therapeutic targets.In this review,we elaborate on the role and regulatory mechanism of Lnc RNA in esophageal cancer,as well as the potential clinical application as a biomarker for diagnosis,treatment and prognosis.
作者 王鹏 申文豪 郭卿 张玮 姚娟 余磊 杨颂 黄俊星 WANG Peng;SHEN Wenhao;GUO Qing;ZHANG Wei;YAO Juan;YU Lei;YANG Song;HUANG Junxing(Department of Oncology,the Fifth Affiliated Hospital of Nantong University,Taizhou 225300)
出处 《南通大学学报(医学版)》 2020年第3期264-271,共8页 Journal of Nantong University(Medical sciences)
基金 江苏省医学创新团队(CXTDA2017042) 泰州市社会发展科技项目(SSF20170215) 泰州市人民医院院级课题(ZL201919)。
关键词 食管癌 长链非编码RNA 机制 生物标志物 esophageal cancer long non-coding RNA mechanisms biomarkers
  • 相关文献

参考文献5

二级参考文献34

  • 1Ferlay J,Shin HR,Bray F. Estimates of worldwide burden of cancer in 2008:Globocan[J].{H}International Journal of Cancer,2010,(12):2893-2917. 被引量:1
  • 2Jemal A,Siegel R,Ward E. Cancer statistics,2009[J].{H}CA-A Cancer Journal for Clinicians,2009,(4):225-249. 被引量:1
  • 3Lepage C,Rachet B,Jooste V. Continuing,rapid increase in esophageal adenocarcinoma in England and Wales[J].{H}American Journal of Gastroenterology,2008,(11):2694-2699. 被引量:1
  • 4Pennathur A,Luketich JD. Resection for esophageal cancer:strategies for optimal management[J].{H}ANNALS OF THORACIC SURGERY,2008,(2):S751-S756. 被引量:1
  • 5Lordick F,Ott K,Krause B J. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:the MUNICON phase Ⅱ trial[J].{H}LANCET ONCOLOGY,2007,(9):797-805. 被引量:1
  • 6Biere SS,van Berge Henegouwen MI,Maas KW. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer:a multicentre,open-label,randomised controlled trial[J].{H}LANCET,2012,(9829):1887-1892. 被引量:1
  • 7Pennathur A,Zhang J,Chen H. The "best operation" for esophageal cancer[J].{H}ANNALS OF THORACIC SURGERY,2010,(6):S2163-S2167. 被引量:1
  • 8Hulscher JB,van Sandick JW,de Boer AG. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus[J].{H}New England Journal of Medicine,2002,(21):1662-1669. 被引量:1
  • 9Omloo JM,Lagarde SM,Hulscher JB. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus:five-year survival of a randomized clinical trial[J].{H}ANNALS OF SURGERY,2007,(6):992-1000. 被引量:1
  • 10Shaheen NJ,Sharma P,Overholt BF. Radiofrequency ablation in Barrett 's esophagus with dysplasia[J].{H}New England Journal of Medicine,2009,(22):2277-2288. 被引量:1

共引文献48

同被引文献6

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部